Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

Structural Mimicry of Receptor Interaction by Antagonistic Interleukin-6 (IL-6) Antibodies.

Blanchetot C, De Jonge N, Desmyter A, Ongenae N, Hofman E, Klarenbeek A, Sadi A, Hultberg A, Kretz-Rommel A, Spinelli S, Loris R, Cambillau C, de Haard H.

J Biol Chem. 2016 Jun 24;291(26):13846-54. doi: 10.1074/jbc.M115.695528. Epub 2016 Apr 27.

2.

Combining somatic mutations present in different in vivo affinity-matured antibodies isolated from immunized Lama glama yields ultra-potent antibody therapeutics.

Klarenbeek A, Blanchetot C, Schragel G, Sadi AS, Ongenae N, Hemrika W, Wijdenes J, Spinelli S, Desmyter A, Cambillau C, Hultberg A, Kretz-Rommel A, Dreier T, De Haard HJ, Roovers RC.

Protein Eng Des Sel. 2016 Apr;29(4):123-33. doi: 10.1093/protein/gzw003. Epub 2016 Mar 5.

PMID:
26945588
3.

Opportunities for functional selectivity in GPCR antibodies.

Webb DR, Handel TM, Kretz-Rommel A, Stevens RC.

Biochem Pharmacol. 2013 Jan 15;85(2):147-52. doi: 10.1016/j.bcp.2012.08.021. Epub 2012 Sep 10. Review.

4.

Targeting TRAIL death receptor 4 with trivalent DR4 Atrimer complexes.

Allen JE, Ferrini R, Dicker DT, Batzer G, Chen E, Oltean DI, Lin B, Renshaw MW, Kretz-Rommel A, El-Deiry WS.

Mol Cancer Ther. 2012 Oct;11(10):2087-95. doi: 10.1158/1535-7163.MCT-12-0366. Epub 2012 Jul 16.

5.

No advantage of cell-penetrating peptides over receptor-specific antibodies in targeting antigen to human dendritic cells for cross-presentation.

Tacken PJ, Joosten B, Reddy A, Wu D, Eek A, Laverman P, Kretz-Rommel A, Adema GJ, Torensma R, Figdor CG.

J Immunol. 2008 Jun 1;180(11):7687-96.

6.

Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy.

Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS.

J Immunol. 2008 Jan 15;180(2):699-705.

7.
8.

Immune modulation by melanoma and ovarian tumor cells through expression of the immunosuppressive molecule CD200.

Siva A, Xin H, Qin F, Oltean D, Bowdish KS, Kretz-Rommel A.

Cancer Immunol Immunother. 2008 Jul;57(7):987-96.

PMID:
18060403
9.

In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models.

Kretz-Rommel A, Qin F, Dakappagari N, Torensma R, Faas S, Wu D, Bowdish KS.

J Immunother. 2007 Oct;30(7):715-26.

PMID:
17893564
10.

In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model.

Pereira CF, Torensma R, Hebeda K, Kretz-Rommel A, Faas SJ, Figdor CG, Adema GJ.

J Immunother. 2007 Oct;30(7):705-14.

PMID:
17893563
11.

CD200 expression on tumor cells suppresses antitumor immunity: new approaches to cancer immunotherapy.

Kretz-Rommel A, Qin F, Dakappagari N, Ravey EP, McWhirter J, Oltean D, Frederickson S, Maruyama T, Wild MA, Nolan MJ, Wu D, Springhorn J, Bowdish KS.

J Immunol. 2007 May 1;178(9):5595-605.

12.

Antibodies selected from combinatorial libraries block a tumor antigen that plays a key role in immunomodulation.

McWhirter JR, Kretz-Rommel A, Saven A, Maruyama T, Potter KN, Mockridge CI, Ravey EP, Qin F, Bowdish KS.

Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1041-6. Epub 2006 Jan 17.

13.

Internalizing antibodies to the C-type lectins, L-SIGN and DC-SIGN, inhibit viral glycoprotein binding and deliver antigen to human dendritic cells for the induction of T cell responses.

Dakappagari N, Maruyama T, Renshaw M, Tacken P, Figdor C, Torensma R, Wild MA, Wu D, Bowdish K, Kretz-Rommel A.

J Immunol. 2006 Jan 1;176(1):426-40.

14.

A nondeletional mechanism for central T-cell tolerance.

Rubin RL, Kretz-Rommel A.

Crit Rev Immunol. 2001;21(1-3):29-40. Review.

PMID:
11642611
15.

Early cellular events in systemic autoimmunity driven by chromatin-reactive T cells.

Kretz-Rommel A, Rubin RL.

Cell Immunol. 2001 Mar 15;208(2):125-36.

PMID:
11333145
16.

Phagocyte-mediated oxidation in idiosyncratic adverse drug reactions.

Rubin RL, Kretz-Rommel A.

Curr Opin Hematol. 2001 Jan;8(1):34-40. Review.

PMID:
11138624
17.

Disruption of positive selection of thymocytes causes autoimmunity.

Kretz-Rommel A, Rubin RL.

Nat Med. 2000 Mar;6(3):298-305.

PMID:
10700232
18.

Initiation of autoimmunity by a reactive metabolite of a lupus-inducing drug in the thymus.

Rubin RL, Kretz-Rommel A.

Environ Health Perspect. 1999 Oct;107 Suppl 5:803-6. Review.

19.

Linkage of immune self-tolerance with the positive selection of T cells.

Rubin RL, Kretz-Rommel A.

Crit Rev Immunol. 1999;19(3):199-218. Review.

PMID:
10422599
21.

Selective protein adduct formation of diclofenac glucuronide is critically dependent on the rat canalicular conjugate export pump (Mrp2).

Seitz S, Kretz-Rommel A, Oude Elferink RP, Boelsterli UA.

Chem Res Toxicol. 1998 May;11(5):513-9.

PMID:
9585482
22.

A metabolite of the lupus-inducing drug procainamide prevents anergy induction in T cell clones.

Kretz-Rommel A, Rubin RL.

J Immunol. 1997 May 1;158(9):4465-70.

PMID:
9127012
23.

Autoimmunity caused by disruption of central T cell tolerance. A murine model of drug-induced lupus.

Kretz-Rommel A, Duncan SR, Rubin RL.

J Clin Invest. 1997 Apr 15;99(8):1888-96.

25.

Idiosyncratic liver toxicity of nonsteroidal antiinflammatory drugs: molecular mechanisms and pathology.

Boelsterli UA, Zimmerman HJ, Kretz-Rommel A.

Crit Rev Toxicol. 1995;25(3):207-35. Review.

PMID:
7576152
26.
27.

Supplemental Content

Loading ...
Support Center